Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies

Expert Review of Clinical Immunology

Volumn 8, Issue 3, 2012, Pages 255-267

  Chiesa, Robert ^a   Veys, Paul ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

hematopoietic cell transplantation; primary immunodeficiency diseases; reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; RITUXIMAB; THYMOCYTE ANTIBODY; TREOSULFAN; YTTRIUM 90;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; ENGRAFTMENT; EVENT FREE SURVIVAL; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY; LOW DRUG DOSE; LOW ENERGY RADIATION; OVERALL SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME;

CHILD; CHIMERISM; CLINICAL PROTOCOLS; DRUG DOSAGE CALCULATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858383192     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.9     Document Type: Review

References (51)

1. Alousi A, de Lima M. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clin. Adv. Hematol. Oncol. 5, 560-570 (2007).
2. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20, 1661-1672 (2006).
3. Rezvani AR, Storb R. Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opin. Biol. Ther. 8, 161-179 (2008).
4. Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park) 13(5), 621-628 (1999).
5. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant. 33(7), 691-696 (2004).
6. Woolfrey A, Pulsipher MA, Storb R. Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency. Curr. Opin. Pediatr. 13(6), 539-545 (2001).
7. Satwani P, Cooper N, Rao K et al. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant. 41(2), 173-182 (2008).
8. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89, 4531-4536 (1997).
9. Amrolia P, Gaspar B, Hassan A et al. Non-myeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96, 1239-1246 (2000).
10. Rao K, Amrolia PJ, Jones A et al. Improved survival after unrelated donor bone marrow transplant in children with primary immunodeficiency using a reduced intensity conditioning regimen. Blood 105, 879-885 (2005).
11. Veys P, Rao K, Amrolia P. Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning. Bone Marrow Transplant. 35 (Suppl. 1), S45-S47 (2005).
12. Cohen J, Gandi M, Naik P et al. Increased incidence of EBV-related disease following pediatric stem cell transplantation with reduced-intensity conditioning. Br. J. Haematol. 129(2), 229-239 (2005).
13. Cohen JM, Sebire NJ, Harvey J et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/ immunodysregulatory disorders with reduced-intensity allogeneic stem cell transplantation. Blood 110(6), 2209-2214 (2007).
14. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of campath-1H in delaying immune reconstitution. Blood 99(12), 4357-4363 (2002).
15. Shenoy S, Grossman WJ, DiPersio J et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 35(4), 345-352 (2005).
16. Straathof KC, Rao K, Eyrich M et al. Haemopoietic stem cell transplantation with antibody-based minimal intensity conditioning regimen for children with severe organ toxicity or DNA repair disorders. Lancet 374(9693), 912-920 (2009).
17. Schulz AS, Glatting G, Hoenig M et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 117(17), 4642-4650 (2011).
18. Ringhoffer M, Blumstein N, Neumaier B et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: Results of a Phase I-II study. Br. J. Haematol. 130(4), 604-613 (2005).
19. Iravani M, Evazi MR, Mousavi SA et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transplant. 40, 105-110 (2007).
20. Jacobsohn DA, Duerst R, Tse W et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 364, 156-162 (2004).
21. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3), 756-763 (1998).
22. Dennison D, Al Zadjali S, Tauro M et al. Reduced-intensity conditioning with single daily dose intravenous busulfan, fludarabine and ATG for patients with primary immunodeficiency. Presented at: 34th Annual Meeting of the European Group for Blood and Marrow Transplantation. Florence, Italy, 30 March-2 April 2008.
23. Horn B, Baxter-Lowe LA, Englert L et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant. 37(3), 263-269 (2006).
24. Ozyurek E, Cowan MJ, Koerper MA et al. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant. 42(2), 83-91 (2008).
25. Güngör T, Albert M, Schanz U et al. Low-dose busulfan/full-dose fludarabine-based reduced-intensity conditioning in 30 high-risk paediatric and adult chronic granulomatous disease patients. Presented at: 37th Annual Meeting of the European Group for Blood and Marrow Transplantation. Paris, France, 3-6 April 2011.
26. Greystoke B, Bonanomi S, Carr TF et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br. J. Haematol. 142(2), 257-262 (2008).
27. Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: More than a BU look-alike. Bone Marrow Transplant. 47(1), 5-14 (2012).
28. Casper J, Knauf W, Blau I et al. Treosulfan/fludarabine: A new conditioning regimen in allogeneic transplantation. Ann. Hematol. 83(Suppl. 1), S70-S71 (2004).
29. Casper J, Knauf W, Kiefer T et al. Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2), 725-731 (2004).
30. Beelen DW, Trenschel R, Casper J et al. Dose-escalated treosulfan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplantat. 35, 233-241 (2005).
31. Slatter MA, Rao K, Amrolia P et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 117(16), 4367-4375 (2011).
32. Burroughs LM, Storb R, Leisenring WM et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: Results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant. 40, 633-642 (2007).
33. Matthes-Martin S, Lion T, Haas OA et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: Potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 17, 1934-1942 (2003).
34. Bradley MB, Satwani P, Baldinger L et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant. 40(7), 621-631 (2007).
35. Barker JN, Weisdorf DJ, DeFor TE et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102(5), 1915-1919 (2003).
36. Morio T, Atsuta Y, Tomizawa D et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br. J. Haematol. 154(3), 363-372 (2011).
37. Cooper N, Rao K, Gilmour K et al. Stem cell transplantation with reduced intensity conditioning for haemophagocytic lymphohistiocytosis. Blood 107(3), 1233-1236 (2006).
38. Cooper N, Rao K, Goulden N et al. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 42(Suppl. 2), S47-S50 (2008).
39. Horne A, Janka G, Maarten Egeler R et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br. J. Haematol. 129, 622-630 (2005).
40. Marsh RA, VaughnG, Kim AH et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 116, 5824-5831 (2010).
41. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD et al. Long-term outcome following hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome: Collaborative study of the European Society for Immunodeficiencies and the European Group for Blood and Marrow Transplantation. Blood 111(1), 439-445 (2008).
42. Filipovich AH, Stone JV, Tomany SC et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: Collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97(6), 1598-1603 (2001).
43. Ochs HD, Filipovich AH, Veys P et al. Wiskott-Aldrich syndrome: Diagnosis, clinical and laboratory manifestations, and treatment. Biol. Blood Marrow Transplant. (Suppl. 1), 84-90 (2008).
44. Pai SY, DeMartiis D, Forino C et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: A single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant. 38, 671-679 (2006).
45. Horwitz ME, Barrett AJ, Brown MR et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N. Engl. J. Med. 344(12), 881-888 (2001).
46. Suzuki N, Hatakeyama N, Yamamoto M et al. Treatment of McLeod phenotype chronic granulomatous disease with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation. Int. J. Hematol. 85(1), 70-72 (2007).
47. Qasim W, Cavazzana-Calvo M, Davies EG et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 123(3), 836-840 (2009).
48. Satwani P, Morris E, Bradley MB et al. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr. Blood Cancer 50(1), 1-8 (2008).
49. Burkholder TH, Colenda L, Tuschong LM et al. Reproductive capability in dogs with canine leukocyte adhesion deficiency treated with nonmyeloablative conditioning prior to allogeneic hematopoietic stem cell transplantation. Blood 108(5), 1767-1769 (2006).
50. Roifman C. Hematopoietic Stem Cell Transplantation for Immunodeficiency, Part 1, An Issue of Immunology and Allergy Clinics. Saunders, PA, USA, 30-115 (2010).
51. Landais P, Newcastle Team. SCETIDE update for SCID and non-SCID HSCT. Inborn Errors Working Party. Presented at: 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation. Lyon, France, 25-28 March 2007.